Balantidiasis Treatment Market

Balantidiasis Treatment Market: Introduction

• Balantidiasis, also known as Balantidium coli infection, is a disorder caused by Balantidium coli, an intestinal protozoan parasite. The parasite is transmitted through the fecal-oral route. Humans can be infected by the parasite by ingesting infective cysts from food and water contaminated with defecation. This infection predominantly affects the large intestine. Diarrhea, weight loss, dysentery, stomach pain, and vomiting are common side-effects of balantidiasis. The infection is observed to be prevalent in rural areas in industrially advanced and developing regions due to water pollution caused by fecal matter of humans and/or pigs. Provision of safe and clean drinking water can prevent the infection from spreading from one person to the other. Anti-infective agents are utilized to treat balantidiasis.  
• Most of the people suffering from Balantidiasis are asymptomatic. Some people may become acutely ill with abnormally high temperatures, vomiting, nausea, abdominal pain, and bloody diarrhea. Such conditions could result in excessive loss of water from the body and extreme exhaustion, especially if B. coli attacks the intestinal lining causing inflammation and possibly ‘crater-like’ areas of damage. In serious cases, the ulcers could be deep enough to puncture the intestinal wall, resulting into the acute inflammation of the peritoneum?the membrane that lines the abdomen (peritonitis). Occasionally, the ulcer may diminish lung function.
• Tetracycline, a common antibiotic drug, is commonly prescribed in the treatment of Balantidiasis. When tetracycline cannot be administered, replacement drug therapy may include iodoquinol or metronidazole. It is not necessary to isolate the person suffering from Balantidiasis. However, the feces of infected individuals must be disposed of so that they don’t came into contact with drinking water or with food supplies.

Key Drivers, Restraints, and Opportunities of Global Balantidiasis Treatment Market

• Rise in prevalence of balantidiasis infection, surge in the trend of swine farming, increase in research & development activities for the diagnosis of the disease, and surge in awareness about the treatment options are major factors that are projected to propel the balantidiasis diagnosis and treatment market during the forecast period. A study conducted by the Stanford University revealed that incidence of the infection has been reported in Bolivia, Papua New Guinea, and the Philippines. The prevalence rate of balantidiasis infection is lower than 1%. Lower incidence rate in major pharmaceutical markets such as North America and Europe and competition between already established players are likely to restrain the global balantidiasis diagnosis and treatment market, in terms of revenue, during the forecast period.  
• Additionally, a lack of hygiene and sanitation in rural areas of developing countries is a significant factor that affects the spread of this disease. Furthermore, increasing awareness regarding the diseases transmitted via faecal-oral route further boosts the market. However, competition among existing market players hampers the entry of new players.

Asia Pacific to Capture Major Share of Global Balantidiasis Treatment Market

Based on region, the global balantidiasis treatment market can be classified into North America (the U.S. and Canada), Europe (including Germany, France, and the U.K.), Asia Pacific (including Australia, China, Japan, and India), Latin America (including Brazil and Mexico), and Middle East & Africa (including GCC countries and South Africa).  The disease is less prevalent in North America due to high sanitation standards and quality of living and hygienic environment. However, the disease is more prevalent in Latin America. Additionally, prevalence of the disease is low in Europe due to high hygiene standards, stringent quality control guidelines, hygienic food and water standards, and government support to maintain good hygiene. Asia Pacific and Latin America are emerging regions for the market; therefore, the market in these regions is projected to expand at a significant pace during the forecast period.

Rapid expansion of the balantidiasis treatment market in these regions can be attributed to the increase in incidence of this infection, poor hygiene conditions, expansion of the healthcare industry, and rise in government investment to develop healthcare infrastructure in these regions. The balantidiasis treatment market in countries such as China, India, and Brazil is projected to expand at a high growth rate during the forecast period due to an increase in awareness among the population about protozoal infections and their treatments. Furthermore, the burden of gastrointestinal diseases is rising due to the increase in the number of pylori infection cases and changes in lifestyle such as consumption of alcohol, smoking, and sedentary work profile.

Key Players Operating in Global Balantidiasis Treatment Market

The global balantidiasis treatment market is highly fragmented, with the presence of various key players.  A large number of manufacturers hold a major share in their respective regions. Major players operating in the global balantidiasis treatment market are:

• Sandoz AG
• 3M
• Johnson & Johnson Services, Inc.
• Abbott
• Koninklijke Philips N.V.
• Siemens Healthcare Private Limited
• GENERAL ELECTRIC COMPANY
• Medtronic, Pfizer Inc.
• Nurotron Biotechnology Co. Ltd.
• Sonova
• BD
• MicroPort Scientific Corporation.
• Akorn
• NuVasive, Inc.
• Globus Medical
• Pfizer, Inc.
• GlaxoSmithKline plc
• Novopharm Limited
• Physicians Total Care, Inc.
• Amneal Pharmaceuticals LLC.
• Sanofi
• Allergan
• Apotex, Inc.

Global Balantidiasis Treatment Market: Research Scope

Global Balantidiasis Treatment Market, by Diagnosis

• Microscopy stool examination
• Sigmoidoscopy
• Biopsy
• Others

Global Balantidiasis Treatment Market, by Product Type

• Tetracycline
• Iodoquinol
• Metronidazole
• Others

Global Balantidiasis Treatment Market, by End-user

• Hospitals
• Diagnostic Centers
• Clinics
• Others

Global Balantidiasis Treatment Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa